RESEARCH TRIANGLE PARK, N.C., Dec. 1, 2021 -- Pappas Capital, a leading investor in early-stage life science and technology companies, today announced the promotions of Cookie Yu, PhD, and Gilbert...
Athersys announces summary results for Phase 1 safety study of its novel obesity drug
News | 02. 27. 2008
Athersys
Athersys, Inc. (Nasdaq:ATHX) today announced top-line results from its Phase 1 clinical trial of ATHX-105, its orally administered drug candidate for the treatment of obesity. ATHX-105 was well- absorbed, providing good drug exposures, well-tolerated up to high doses, and had no negative effect on cardiovascular, hematology or other clinical parameters.
